智通财经APP讯，上海医药(02607)公布，近日，公司下属上海医药集团青岛国风药业股份有限公司(以下简称“上药国风”)的温经汤颗粒(规格：每袋相当于饮片 20g)收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2025S01230)，该药品获得批准生产。
温经汤颗粒处方来源于宋•陈自明《妇人大全良方》，并已列入《古代经典名方目录(第一批)》。该药品温经补虚，化瘀止痛。用于血海虚寒，气血凝滞证。症见妇人月经不调，脐腹作痛，脉沉紧。2024 年 7 月上药国风就该药品向国家药监局提出注册上市申请，并获受理。截至本公告日，公司针对该药品已投入研发费用约人民币 469 万元。
根据国家相关政策，按新注册分类获批的中药新药在医保支付及医疗机构采购等领域将获得更大的支持力度。因此上药国风的温经汤颗粒获得批准生产，为企业提供了新产品，提升了企业的市场竞争力，同时为后续中药复方制剂新药的研制和注册积累了宝贵的经验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.